🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,257 results for “First” Clear

  1. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  2. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  3. Keverprazan

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    phase 1 small molecule active

    1 trial

  4. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  5. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

  6. LVIVO-TaVec200 product

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  7. LY007

    The First People's Hospital of Lianyungang

    B-NHL

    phase 1 small molecule active

    1 trial

  8. Lansoprazole capsules

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 1 small molecule completed

    1 trial

  9. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  10. Light Power Density and Light Duration 40 mW/cm²*1000s

    The First People's Hospital of Lianyungang

    Healthy Adult Subjects

    phase 1 other completed

    1 trial

  11. Low dose ET019002- T Cells

    The First People's Hospital of Lianyungang

    B-Cell Malignancies

    phase 1 mab active

    1 trial

  12. Metformin

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    phase 1 small molecule active

    1 trial

  13. NGGT002 Injection

    The First People's Hospital of Lianyungang

    Phenylketonurias

    phase 1 gene therapy active

    1 trial

  14. Oxycodone Medication First

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Drug Abuse (Not Dependent)

    phase 1 small molecule completed

    1 trial

  15. PRG2302

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  16. Pemetrexed

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastases

    phase 1 small molecule completed

    1 trial

  17. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  18. Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies (NHLs)

    phase 1 other active

    1 trial

  19. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  20. Placebo

    The First People's Hospital of Lianyungang

    Asthma

    phase 1 small molecule active

    1 trial

  21. Prizloncabtagene Autoleucel

    The First People's Hospital of Lianyungang

    Non-Hodgkin's B-cell Lymphoma

    phase 1 mab active

    1 trial

  22. Probiotic

    The First People's Hospital of Lianyungang

    Microbiota

    phase 1 small molecule active

    1 trial

  23. Proxalutamide

    The First People's Hospital of Lianyungang

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  24. REGEND001

    The First People's Hospital of Lianyungang

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources